Major R&D Pipeline: 3ADCs

ENHERTU®: Breast cancer DESTINY-Breast03 study (HER2+, 2L, Ph3): TLR of interim analysis anticipated in FY2021 Q2 as originally planned DESTINY-Breast09 study (HER2+, 1L, Ph3): First patient dosed in June Daiichi-Sankyo Presented interim results of BEGONIA study and subgroup analysis data of DESTINY-Breast01 study in patients with brain metastasis at ASCO 2021 BEGONIA interim results (durvalumab combo) 20 DESTINY-Breast01 brain met subgroup analysis 100 80 n=15 Progressive Disease Partial Response -20 Change in target lesion from baseline (%) -60 Best response ▲ Partial response (confirmed) PD-L1 expression 5% cutoff Unknown Negative Positive 60 60 40 40 20 20 0 -20 -40 -60 -80 Stable Disease -100 0 6 12 18 24 30 Weeks 36 42 48 54 HO PD SD PR 60 60 * If the best percentage change from baseline of target lesions cannot be calculated due to progression, withdrawal or death, the value is imputed at +20% Number of subjects that had the opportunity to complete at least two on-treatment disease assessments or have PD or death 3 patients with reported baseline measurements had no change over time. 2 patients with brain metastases at baseline did not have sufficient data to evaluate response in the brain and are not shown. ● Stable disease (≥5 wks) Progressive disease -80- Not yet evaluables Durable responses were observed in patients with stable, treated brain metastases. The confirmed ORR was 66.7% in Arm 6 (HER2 low/ER-/PR- BC, ENHERTU® + durvalumab) of BEGONIA study. BC: breast cancer, ER: estrogen receptor, ORR: objective response rate, PR: progesterone receptor, TLR: top line results 16

View entire presentation